ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 34638374

Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling.

Xiao JF and 3 others. Cancers (Basel), 2021. Cited by 41 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling. Papers, record 34638374. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34638374

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2021
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
41
iCite
Relative citation ratio, by iCite
2.42
iCite
Revised in PubMed
2023-09-21
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Xiao JFJin-Fenhttps://orcid.org/0000-0003-3366-5984
2Caliri AWAndrew W
3Duex JEJason E
4Theodorescu DDan

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References91

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
122,837,387Transforming fusions of FGFR and TACC genes in human glioblastoma.Science2012https://conductscience.org/library/papers/22837387PubMed
233,538,338Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin2021https://conductscience.org/library/papers/33538338PubMed
331,340,094Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.N Engl J Med2019https://conductscience.org/library/papers/31340094PubMed
426,646,757A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors.Ann Oncol2016https://conductscience.org/library/papers/26646757PubMed
532,203,698Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.Lancet Oncol2020https://conductscience.org/library/papers/32203698PubMed
625,872,978Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.Cancer2015https://conductscience.org/library/papers/25872978PubMed
79,428,423Fibroblast growth factor 10 (FGF10) and branching morphogenesis in the embryonic mouse lung.Development1997https://conductscience.org/library/papers/9428423PubMed
824,048,522Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice.Sci Transl Med2013https://conductscience.org/library/papers/24048522PubMed
929,848,605Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.Cancer Discov2018https://conductscience.org/library/papers/29848605PubMed
1016,597,617Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family.J Biol Chem2006https://conductscience.org/library/papers/16597617PubMed

1 to 10 of 91

See all 91 references

Cited by27

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 41 citations.

PMIDTitleJournalYearIn PapersSource
42,649,945Development and Broad Application of a Double Drop-Off ddPCR Assay for Simultaneous Detection of Four FGFR3 Mutations in Tissue and Liquid Biopsy Samples.Cancers (Basel)2026https://conductscience.org/library/papers/42649945PubMed
42,588,034Nutraceuticals in Uro-Oncology: A Structured Expert Review and Precision-Oriented Framework.Nutrients2026https://conductscience.org/library/papers/42588034PubMed
42,584,173FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma.Clin Cancer Res2026https://conductscience.org/library/papers/42584173PubMed
42,271,082Comparative efficacy and safety of carboplatin-based versus cisplatin-based chemotherapy in muscle-invasive and advanced bladder cancer: A systematic review and meta-analysis.Eur J Clin Pharmacol2026https://conductscience.org/library/papers/42271082PubMed
41,514,604FGFR Aberrations in Solid Tumors: Mechanistic Insights and Clinical Translation of Targeted Therapies.Cancers (Basel)2025https://conductscience.org/library/papers/41514604PubMed
41,154,422Navigating Therapeutic Landscapes in Urothelial Cancer: From Chemotherapy to Precision Immuno-Oncology.Cancers (Basel)2025https://conductscience.org/library/papers/41154422PubMed
41,056,445Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study.Oncologist2025https://conductscience.org/library/papers/41056445PubMed
40,943,615Current and Emerging Therapies for Targeting the ERK1/2 & PI3K Pathways in Cancer.Int J Mol Sci2025https://conductscience.org/library/papers/40943615PubMed
40,874,920Deregulated miR-145 and miR-27b in Hutchinson-Gilford progeria syndrome: implications for adipogenesis.Aging (Albany NY)2025https://conductscience.org/library/papers/40874920PubMed
40,735,045Histological and immunohistochemical approaches to molecular subtyping in muscle-invasive bladder cancer.Front Oncol2025https://conductscience.org/library/papers/40735045PubMed

1 to 10 of 27

See all 27 cited by

Genes50

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ABL125PubTator's text mininghttps://conductscience.org/library/genes/25NCBI Gene
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
ALK238PubTator's text mininghttps://conductscience.org/library/genes/238NCBI Gene
ANGPT1284PubTator's text mininghttps://conductscience.org/library/genes/284NCBI Gene
CD27429,126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
DAG11,605PubTator's text mininghttps://conductscience.org/library/genes/1605NCBI Gene
DUSP61,848PubTator's text mininghttps://conductscience.org/library/genes/1848NCBI Gene
EGFR1,956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
ERBB22,064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
ERBB32,065PubTator's text mininghttps://conductscience.org/library/genes/2065NCBI Gene

1 to 10 of 50

See all 50 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34638374

GET https://conductscience.org/api/papers/v1/34638374/references?page=2

API referenceFor AI assistants